# Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas

> **NCT00586508** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 81 (actual)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** bevacizumab
- **DRUG:** Enzyme-inducing antiepileptic drugs (EIAED)
- **DRUG:** Non-enzyme inducing antiepileptic drugs (NEIAED)

## Key facts

- **NCT ID:** NCT00586508
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2020-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00586508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00586508, "Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00586508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*